



Revived interest in bacteriophages
Phages have a track record of being left behind whenever science moves on 
to other things. But will the inexorable spread of antibiotic resistance lead to a 
revival of their role as antibacterial therapeutics? Michael Gross investigates.Tree life: The entire horse chestnut tree is the environment that shapes the mutual adap-
tation of Pseudomonas syringae bacteria and their phages, as research from Koskella and 
colleagues has shown. (Photo: Photolibrary.) In the unlikely setting of Oxford 
University’s Zoology Department, 
NERC research fellow Britt Koskella 
studies horse chestnut trees, their 
bacterial pathogens and, most 
importantly, the bacteriophages that 
infect those bacteria. It’s all ecology, 
she says, which fits in with the 
interests of the department. 
But why horse chestnuts? “A lot 
of work on phages has been done in 
water,” Koskella explains, “but in the 
leaves of the chestnut tree we have 
a well-defined environment where 
we can pin down the interactions of 
phages and their hosts.” The bacterial 
hosts are Pseudomonas syringae, 
which cause bleeding canker disease 
in the trees. 
Koskella and her colleagues wanted 
to find out about the length scale on 
which bacteria and phages adapt to 
each other. In other words, is their 
frame of reference the border of the 
leaf, the entire leaf, or perhaps the 
entire tree? They found out that the 
tree is an important unit defining 
the relationship between phage and 
host. Phages were highly efficient 
at infecting bacteria sampled from 
elsewhere in the same tree, but much 
less so for bacteria from other trees 
(Am. Nat. (2011), 177, 440-451). 
Building on these findings, Koskella 
is now further exploring the ecology 
of phages in the chestnut tree to 
see whether their presence actually 
helps the tree fight off the disease. 
She is also interested in agricultural 
applications of phages, for instance 
in cultivation of tomatoes. “One of 
our motivating factors for this work is 
determining whether phages would 
be good candidates for control of 
plant pathogens in naturally variable 
populations,” Koskella explains. There 
is, she says, a revived interest in 
bacteriophages which can build on a 
long but frequently interrupted history 
of achievements. 
A brief history of bacteriophages 
Phages as natural antibacterial 
agents were discovered several times, but among the discoverers, 
French-Canadian microbiologist 
Felix d’Herelle was the only one 
who ardently believed that these 
were viruses. He coined the word 
‘bacteriophage’ and propagated 
this view since 1917, so he can 
take credit for the concept of 
viruses infecting bacteria. Losing 
no time in proceeding to the clinic, 
d’Herelle tested phage cocktails 
against dysentery in 1919, and set 
up commercial production of phage 
products marketed by the company 
that later became L’Oréal. 
Following the introduction of 
penicillin (in the 1940s) and other 
antibiotics, phages fell into oblivion 
in Western Europe and in North 
America, but their use continued in 
the Soviet Union. Specifically, the 
capital of Georgia, Tbilisi, hosted a 
dedicated phage institute founded in 
1923 by Georgi Eliava, with support 
from d’Herelle. Even though Eliava 
was executed in 1937, the institute 
survived and is today named after 
him. Research into phage therapy and indeed treatment using phage 
cocktails continued to thrive there and 
in Poland. However, much of the work 
was published in Russian journals 
only and thus never came to the 
attention of western scientists. 
Phages had another spell in the 
spotlight beginning in the 1940s 
when physicist turned geneticist 
Max Delbrück started studying their 
genetics, and the phages lambda 
and T4 became widely known and 
well-studied models of molecular 
biology. In 1967, for instance, research 
with lambda phages led to the first 
isolation of a DNA-binding protein 
(lambda repressor) — independently 
achieved by Mark Ptashne and Walter 
Gilbert at Harvard. Phage research 
explicitly focused on a small number 
of model systems and thus didn’t 
expand into a broader interest in the 
evolution, diversity, or usefulness of 
phages. Molecular biology moved on 
to more complex systems as soon as 
it had the tools to do so.
Similarly, genome sequencing 
started out with phages MS2 (RNA) 
and f-X174 (the first DNA genome), 
but then swiftly moved on to cellular 
organisms, leaving the world of 
phages mostly unchartered territory. 
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Bacteria eater: T2 bacteriophages have land-
ed on an Escherichia coli cell and prepare to 
inject their genetic material into it. (Photo: 
Lee D. Simon/Science Photo Library.)
Georgian capital: Research into therapeutic applications of bacteriophages has been conduct-
ed in Tbilisi, Georgia, for almost 80 years. (Photo: Photolibrary.)Only in recent years, following 
the application of environmental 
genomics to various biotopes, have 
researchers started to realise that 
phages are by far the most numerous 
biological entity on our planet and 
play important roles in ecological 
networks. For instance, research 
into deep sea samples published in 
2008 showed that in nutrient-poor 
biotopes phages account for over 
80% of bacterial mortality, and that 
the release of nutrients from bacterial 
cells after lysis by phages creates a 
microbes-only food web that excludes 
higher organisms and enables the 
bacterial community to survive in spite 
of the poor food supply. 
The picture emerging from genomic 
studies is that there may be ten 
times more phages than cellular 
organisms on our planet. Even in our 
own bodies, colonised by many more 
bacteria than we have cells, there 
are 100 phages for every bacterium. 
Horizontal gene transfer operated 
by phages has probably shaped 
evolution in many ways, which we are 
only beginning to understand, adding 
further complexity to the ‘tree of life’ 
image based on Darwinian evolution, 
as phage researcher Harald Brüssow 
from the Nestlé Research Centre in 
Lausanne, Switzerland, has recently 
outlined in a review (Phil. Trans. R. 
Soc. B (2009), 364, 2263-2274). 
In sickness and in health
If we are already infested by billions 
of phages without ever noticing, adding a few more to fight disease 
should be quite safe, the proponents 
of phage therapy argue. Indeed, 
the long history of phage therapy, 
while a bit short on the double-blind, 
placebo-controlled studies that 
would live up to modern standards, 
doesn’t contain any records of 
adverse effects. 
Biologically, that does make sense, 
as phages are so highly specialised 
for a specific species or even strain 
of bacteria that they have no way 
of interacting with eukaryotic cells. 
However, one would be well advised 
to use lytic phages — the kind that 
instantly lyses and thus kills the 
bacterial host — as opposed to 
lysogenic phages, which have the 
habit of inserting their DNA (known 
as a prophage) into the host genome, 
which can lead to the transfer of 
virulence traits and all kinds of 
mischief. 
The epidemiology of cholera 
illustrates this crucial difference. The 
gene for cholera toxin, one of several 
virulence factors required for Vibrio 
cholerae to become pathogenic, is transmitted by a lysogenic 
phage. However, among the ~200 
bacteriophages that infect Vibrio 
(collectively known as vibriophages), 
there are also lytic phages that can 
control the spread of the bacterium 
and don’t alter its genome. 
Under the auspices of the  
so-called Bacteriophage Inquiry 
held in India from 1928 to 1934, 
researchers studied possible 
treatment and prevention of cholera 
using vibriophages. The study 
reported a 15-fold reduction in 
mortality, but the approach was 
abandoned after the advent of 
antibiotics and rehydration therapy. 
The recent cholera outbreak in 
Zimbabwe has revived interest in 
research into the dynamics of the 
relationship between phages, Vibrio 
and human hosts, based on the 
hypothesis that vibriophages, while 
unable to clear Vibrio infections from 
human intestines, may help to block 
transmission (Nat. Rev. Microbiol. 
(2009), 7, 693-702). A complicating 
factor is that natural phage 
populations seem to be playing a 
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Deadly companion: Cholera, which still causes many deaths in developing countries, gets 
its virulence factors from lysogenic phages, but lytic phages may help to control its spread. 
(Photo: Thony Belizaire/Getty Images.)large role in shaping the evolution 
of Vibrio cholerae by driving major 
changes in serotype prevalences. 
This implies that understanding the 
natural dynamics will be critical 
to using phage therapy at the 
population scale.
Replacement for antibiotics?
Additional interest in phage therapy 
is based on the current problems 
surrounding the spread of antibiotic 
resistance genes. In a development 
that experts have been predicting 
since the mid-1990s, inconsiderate 
use of available antibiotics has led to 
widespread occurrence of resistant 
strains such as the multidrug-
resistant Staphylococcus aureus, also 
known as MRSA or, in the popular 
press, as “hospital superbug”. So far, 
the standard response has been to 
introduce new antibiotics, but at the 
moment the pipelines of the pharma 
industry aren’t exactly overflowing 
with new antibiotics, and there are 
fears that the infectious diseases may 
make a comeback.
This developing crisis has 
generated fresh interest in everything 
that fights bacteria. One of the 
alternative approaches, so called 
pilicides, consists of stopping 
pathogenic bacteria from growing 
the ‘hairs’ that they need to attach 
themselves to their hosts. The 
unique selling point is that this 
treatment doesn’t kill bacteria in 
the environment (like any leaked 
antibiotic would), so there is less 
selection pressure in favour of 
resistance. However, this approach 
is still very much in the domain of 
fundamental research. 
So why not use phages, which 
have been known to mankind 
for almost a century now, as an 
alternative to antibiotics? Sceptics 
point to the unwieldy size of a phage 
(compared with small-molecule 
drugs), which bars them from 
entering human organs and cells. 
“The phage therapy field has not 
been able to move to phase I clinical 
trials for any systemic application, 
and I do not see this happening any 
time soon,” says Kim Lewis, director 
of the Antimicrobial Discovery 
Center at Northeastern University in 
Boston, Massachusetts. “There is 
little evidence that phage therapy will 
help us solve the antibiotic resistance 
crisis,” he concludes. The size issue 
may indeed limit phage therapy to the more accessible parts of a patient 
(but these are also more accessible 
to bacteria, so more likely to need the 
phage treatment).
Critics also like to emphasize 
the fact that bacteria will develop 
resistance against phages. This 
is where ecological research like 
Koskella’s work on chestnut trees 
comes in handy. While it is clear 
that phages are intrinsically unable 
to wipe out their hosts, a better 
understanding of their ecology may 
enable researchers to find out which 
additional intervention might do 
that once the phage has reached an 
equilibrium with the bacterium.  
“I think that combining treatments  
is the way forward,” says Koskella. 
In the best case, the immune system 
might get the upper hand once the 
bacterial infection is weakened by 
fighting its own disease. 
There is a simple economic reason 
why pharma and biotech companies 
in the western world haven’t been 
keen on phages. Something that 
is (to a certain extent) alive and 
co-evolves with the pathogen is 
much harder to patent and exploit 
economically than a well-defined 
small molecule made industrially — a 
problem very familiar to all who work 
in medical applications of stem cell research. Oxford phage researcher 
Angus Buckling, who published a 
recent report describing phage–host 
coevolution in soil (Science (2011), 
332, 106-109) and was also involved 
with the chestnut paper, says he’d 
rather not patent phage cocktails, 
because “this could then stop the 
very successful cottage industry of 
phage therapy in the Eastern Europe 
and other places around the world”.
Phage & co. 
Nevertheless, there are now a few 
western companies testing the 
waters. Omnilytics, based in Salt 
Lake City, Utah, USA, is developing 
phage cocktails to treat bacterial 
diseases of agricultural crops that 
have become resistant to traditional 
treatments. 
In 2006, US company Intralytix, 
based in Baltimore, Maryland, gained 
FDA (Food and Drug Administration) 
approval for a cocktail of six phages 
that can be sprayed onto ready-to-eat 
food products, in order to control 
the food-borne bacterium Listeria 
monocytogenes. This February, 
Intralytix received regulatory 
clearance from the FDA for a  
phage-based food safety product 
called EcoShield, which is effective 
against Escherichia coli O157:H7. 




Nancy Knowlton, getting ready for a night 
dive in Panama. (Photo by Christian Ziegler.)Alexander Sulakvelidze, Chief 
Scientist at Intralytix and one of 
its co-founders, says phages are 
a very safe and natural way of 
protecting food against bacteria. 
“The concept of using phages for 
improving food safety is based on 
simply applying phages back onto 
the foods in the right concentration, 
at the right place, and at the right 
time,” Sulakvelidze explains. “Thus, 
applying lytic phages onto foods to 
eliminate or significantly reduce the 
levels of pathogenic bacteria in those 
foods is one of the most, if not the 
most, environmentally-friendly, safe, 
and effective approaches available 
today,” he concludes.
In the UK, the company Targeted 
Genetics has just changed its 
name to AmpliPhi Biosciences 
to emphasize its bacteriophage 
technology. Earlier this year, the 
company had acquired Biocontrol, 
whose lead product, a phage 
treatment for chronic ear infections, 
has just completed a clinical phase 
I and II trial. The company is also 
developing a phage treatment to 
combat Pseudomonas lung infections 
in patients with cystic fibrosis. 
Meanwhile, international 
corporation Nestlé is conducting a 
clinical trial using a cocktail of T4 
phages against childhood diarrhoea 
in Bangladesh. The randomized, 
double-blind, placebo-controlled 
trial overseen by Shafiqul Sarker in 
Dhaka, Bangladesh, enrols around 
450 boys aged six months to two 
years with diarrhoea, provided 
they test negative for cholera and 
rotavirus. Equal numbers of the 
children will randomly receive either 
a new T4 phage cocktail or an 
established phage product from the 
Russian company Microgen, or a 
rehydration solution as placebo. The 
trial is due to be completed in June 
this year. 
Even if phage cocktails turn out 
to be no satisfactory solution, there 
is still the opportunity to learn from 
phages and to borrow some of their 
molecular arsenal, such as the lysins 
(FEMS Microbiol. Rev. (2009), 33, 
801-819). In any case, it is clear, 
concludes Koskella, that “in our fight 
against pathogenic bacteria we have 
viruses on our side”.
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web 
page at www.michaelgross.co.uk.Nancy Knowlton is the Sant Chair of 
Marine Science at the Smithsonian’s 
National Museum of Natural History. 
An undergraduate first at Smith and 
then Harvard, she headed west for 
her PhD to the University of California 
at Berkeley, where she studied with 
Roy Caldwell. After a NATO post-doc 
with Geoff Parker, she spent five years 
at Yale, 14 years at the Smithsonian 
Tropical Research Institute in Panama, 
and nine years at the Scripps 
Institution of Oceanography, before 
taking her current position in 2007. 
Her research on coral reefs has 
taken her to tropical seas around the 
planet. She is the author of ‘Citizens 
of the Sea’, published by National 
Geographic in 2010.
How did you come to be interested 
in the ocean? I have been interested 
in science for as long as I can 
remember. My grandfather was a 
medical doctor who loved to tease 
me with scientific enigmas and taught 
me to fish, and although my parents 
were not scientists or academics, 
they always supported me. I still 
vividly remember the thrill as a kid 
of seeing the rings of Saturn through 
my telescope and watching Sputnik 
cross the sky. An inspirational high 
school teacher, Mr. Vazquez, turned 
me in the direction of biology, plus my 
father was never happier than when 
gazing at the ocean, so I spent many 
unsupervised summers wandering on 
the shores of Long Island Sound. Even 
so, it wasn’t until after graduating, 
when I took a year off from school to 
work for Ruth Turner at Harvard, that I 
found my passion. Like many women 
scientists of her generation, she had 
to struggle for her success — she 
was the first woman to go down in the 
Alvin submarine, and she inspired me 
to learn to SCUBA dive. 
How would you describe your 
career? I actually feel I have had 
four careers. I started off at Yale 
where I threw myself into teaching 
undergraduates. I loved the small lab/
field course that I created there and I 
still occasionally hear from or of the 
students I trained. But my soon-to-be 
husband was a professor at Johns Hopkins, and we ultimately took two 
research jobs with the Smithsonian in 
Panama to be together. I think most 
of our colleagues thought we were 
crazy, but it is where I really became 
a scientist — finally my laboratory, the 
coral reef, was in my backyard. Later, 
when we moved to Scripps and away 
from coral reefs, I focused my creative 
energies on founding the Center for 
Marine Biodiversity and Conservation 
and started both Masters and PhD 
programs in this field. Now once 
again I am in a very different setting, 
a museum on the Mall in Washington 
DC, where I combine research with 
public outreach. I think the moral here 
is, when deciding what to do, take 
advantage of the strengths of where 
you are. 
What are your most memorable 
career moments? Well, I have to 
say that being taken hostage with 
my four-year-old daughter and nine 
other researchers at the Smithsonian’s 
San Blas station during the invasion 
of Panama was pretty memorable. 
When your job description ends with 
“… and other duties as assigned”, 
somehow you never imagine being 
force marched at gun point, barefoot, 
over the continental divide, carrying 
your data and your daughter’s favorite 
stuffed animal.
More conventionally, I have had a lot 
of memorable moments underwater, 
